Pulmonx (LUNG) Net Cash Flow Growth (3y) (2022 - 2025)
Pulmonx (LUNG) Net Cash Flow Growth (3y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 269.22% |
| 10 | Pulmonx | 93.95 Mn | 24.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 27.53% |
| Jun 30, 2025 | 30.12% |
| Mar 31, 2025 | 29.95% |
| Dec 31, 2024 | 29.79% |
| Sep 30, 2024 | 26.00% |
| Jun 30, 2024 | 14.34% |
| Mar 31, 2024 | 15.42% |
| Dec 31, 2023 | -27.20% |
| Sep 30, 2023 | -25.74% |
| Jun 30, 2023 | -32.33% |
| Mar 31, 2023 | 80.01% |
| Dec 31, 2022 | -127.11% |